SRI INTERNATIONAL - NAID/NIH PRECLINICAL DRUG DEVELOPMENT EXPERTISE
Key Details
Description
NAID/NIH PRECLINICAL DRUG DEVELOPMENT EXPERTISE
Context & Analysis
Department of Health and Human Services obligated $4,499,443 to SRI INTERNATIONAL for naid/nih preclinical drug development expertise. The award is classified under NAICS 541611. Competition extent: full and open competition with 1 offer received. Performance is located in CA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541611 — related awards are listed below.
Contractor Information
Similar Awards
IGF::OT::IGF-PPHF-2013-ELIGIBILITY SUPPORT
SERCO INC
$1.2B
IGF::OT::IGF FOR OTHER FUNCTIONS
HIGHPOINT DIGITAL, INC.
$839.9M
IGF::OT::IGF CCIIO ENROLLMENT RESOLUTION AND RECONCILIATION, FORM 1095-A DATA REPORTING TASK ORDER
COGNOSANTE, LLC
$315.5M
IGF::OT::IGF ELIGIBILITY APPEALS OPERATIONS SUPPORT
MAXIMUS FEDERAL SERVICES, INC.
$286.9M
IGF::OT::IGF THE CERT PROGRAM CALCULATES BI-ANNUAL IMPROPER PAYMENT RATES BASED ON THE RESULTS OF THE REVIEWS CONDUCTED. THESE RATES INCLUDE AN OVERALL NATIONAL MEDICARE FFS IMPROPER PAYMENT RATE AND IMPROPER PAYMENT RATES FOR EACH CLAIM TYPE [PART A INPATIENT HOSPITAL PROSPECTIVE PAYMENT SYSTEM (PPS); PART A EXCLUDING INPATIENT HOSPITAL PPS; PART B; AND DURABLE MEDICAL EQUIPMENT, PROSTHETICS, ORTHOTICS, AND SUPPLIES (DMEPOS)]. THE CERT PROGRAM ENSURES A STATISTICALLY VALID RANDOM SAMPLE; THEREFORE, THE IMPROPER PAYMENT RATE CALCULATED FROM THIS SAMPLE IS CONSIDERED TO BE REFLECTIVE OF ALL OF CLAIMS PROCESSED BY MEDICARE FFS PROGRAM DURING THE REPORT PERIOD. CMS ALSO USES THE CERT PROGRAM TO PERFORM SPECIAL STUDIES AND SUPPLEMENTAL MEASUREMENTS TO DETERMINE THE IMPROPER PAYMENT RATES OF PARTICULAR CLAIM TYPES. CALCULATIONS OF THESE RATES FACILITATE CMS ABILITY TO TAKE APPROPRIATE CORRECTIVE ACTIONS TO REDUCE IMPROPER PAYMENTS.
EMPOWER AI, INC.
$230.2M
Stay Updated
Get notified about new opportunities matching your interests.